Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, has announced its plans to take direct compression formulation to the next level with the launch of two new mannitol products at this year’s edition of CPHI. In addition, the company will demonstrate its commitment to unlocking healthier futures with a focus on patient centricity. As a sponsor of this year’s conference program, visitors are invited to join Roquette experts for a number of exclusive presentations, highlighting topics including solutions to tackle medication non-adherence and optimization of drug delivery systems with the right high-quality excipients.

Unveiling the new standard in direct compression
Roquette invites attendees at CPHI to discover the potential of high quality mannitol-based products designed to unlock innovative application areas, like controlled release tablets, and optimize direct compression processes.

“As a leading global pharmaceutical excipients supplier, it’s important for us to continuously harness the power of innovation to support our customers’ evolving formulation needs,” comments Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette. “We’re delighted to bring two brand-new solutions to the market that will open up new development opportunities in the direct compression space. We’ve spent significant time understanding our customers’ pain points, as well as those of the wider industry, so we can bring these specialized products to fruition and help to solve some of the toughest drug delivery challenges.”

Putting patient needs in the spotlight
For oral formulations, taste, appearance, and smell have a direct impact on medication adherence. This not only limits patients from leading a healthy life, but also affects the commercial bottom line. Smaltz explains: “Drug adherence is a significant issue today, with medication non-adherence accounting for half of all treatment failures in the USA.[1] That’s why we’re putting patient centricity in the spotlight – we believe the world needs access to more innovative drug delivery systems and applications that support patient compliance. Achieving this vision demands all of our participation and CPHI is the perfect platform through which to share this message.”

On November 3, Roquette will take center stage as part of the ‘Patient Centricity’ track – Smaltz, alongside other industry experts, will participate in a roundtable exploring the latest news and insights on consumer health, including how the pharmaceutical industry can better engage patients in education and decision-making. Arnaud Verhaeghe, Head of Oral Dosage at Roquette will then present the latest innovations addressing patient compliance and enhancing consumer experience.

Visit Roquette at stand 80C90 to connect with the team and experience its cutting-edge solutions for the pharmaceutical market.

About Roquette: “Offering the best of nature”
Roquette is a family-owned global leader in plant-based ingredients, a pioneer of plant proteins and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 100 countries, has a turnover of 3.9 billion euros, and employs more than 8,000 people worldwide.

Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them, we enable a whole new plant protein cuisine; we offer pharmaceutical solutions that play a key role in medical treatments; and we develop innovative ingredients for food, nutrition, and health markets. We truly unlock the potential of nature to improve, cure and save lives.

Thanks to a constant drive for innovation and a long-term vision, we are committed to improving the well-being of people all over the world. We put sustainable development at the heart of our concerns, while taking care of resources and territories. We are determined to create a better and healthier future for all generations.

Report Abuse